Inside information announcement - product revenue in the third quarter of 2026
Filed with HKEX · Stock code 1801 ·
6ix is reading this filing.
View original source (HKEXnews)Innovent Biologics, Inc. on 6ix
Earlier from Innovent Biologics
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- 2026 Interim report
- Voluntary announcement - Jaypirca (pirtobrutinib) approved in China for a new indication in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) across all lines of therapy
- Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
- Altruist Biologics' Suzhou Site Receives EMA GMP Certification, Enabling Product Commercialization for the European Market
Follow Innovent Biologics into a list and get an email when it puts out news.
Follow Innovent Biologics